Clinical Trials Directory

Trials / Terminated

TerminatedNCT02744833

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

A Randomized Phase I/II Study to Assess the Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-Level Deep Venous Thrombosis

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
2 (actual)
Sponsor
GlycoMimetics Incorporated · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the safety profile of GMI-1271 and its effect on thrombus resolution in patients with distal calf vein Deep Venous Thrombosis (DVT).

Conditions

Interventions

TypeNameDescription
DRUGGMI-1271
DRUGEnoxaparin Sodium (Lovenox®)

Timeline

Start date
2016-07-01
Primary completion
2016-11-01
Completion
2016-11-01
First posted
2016-04-20
Last updated
2019-06-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02744833. Inclusion in this directory is not an endorsement.